These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 9845270

  • 1. Effect of WEB 2086-BS, an antagonist of platelet-activating factor receptors, on retinal vascularity in diabetic rats.
    de la Cruz JP, Moreno A, Ruiz-Ruiz MI, García-Campos J, Sánchez de la Cuesta F.
    Eur J Pharmacol; 1998 Oct 30; 360(1):37-42. PubMed ID: 9845270
    [Abstract] [Full Text] [Related]

  • 2. The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus.
    De La Cruz JP, Moreno A, Mérida F, García Campos J, Sánchez de la Cuesta F.
    Thromb Res; 1996 Feb 01; 81(3):327-37. PubMed ID: 8928090
    [Abstract] [Full Text] [Related]

  • 3. Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus.
    De La Cruz JP, Moreno A, Ruiz-Ruiz MI, Sánchez De La Cuesta F.
    Thromb Res; 2000 Feb 01; 97(3):125-31. PubMed ID: 10680643
    [Abstract] [Full Text] [Related]

  • 4. Effects of clopidogrel and ticlopidine on experimental diabetic ischemic retinopathy in rats.
    De La Cruz P, Arrebola M, González-Correa A, Martinez-Cerdán E, Moreno A, de la Cuesta FS.
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb 01; 367(2):204-10. PubMed ID: 12595963
    [Abstract] [Full Text] [Related]

  • 5. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
    Kagoshima M, Tomomatsu N, Iwahisa Y, Yamaguchi S, Kawakami Y, Terasawa M.
    Pharmacology; 1997 May 01; 54(5):261-70. PubMed ID: 9380772
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
    Takehara S, Mikashima H, Muramoto Y, Terasawa M, Setoguchi M, Tahara T.
    Prostaglandins; 1990 Dec 01; 40(6):571-83. PubMed ID: 1965554
    [Abstract] [Full Text] [Related]

  • 7. Effects of terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, on retinal vascularity in diabetic rats.
    De La Cruz JP, Jebrouni N, López-Villodres JA, Muñoz-Marín J, Guerrero A, González-Correa JA.
    Diabetes Metab Res Rev; 2012 Feb 01; 28(2):132-8. PubMed ID: 22423383
    [Abstract] [Full Text] [Related]

  • 8. Effects of ditazol on the vascular retinal pattern in experimental diabetes in rats.
    Moreno A, De La Cruz JP, Mérida F, García Campos J, Sánchez de la Cuesta F.
    Haemostasis; 1995 Feb 01; 25(4):166-71. PubMed ID: 7557655
    [Abstract] [Full Text] [Related]

  • 9. Effect of aspirin on prostanoids and nitric oxide production in streptozotocin-diabetic rats with ischemic retinopathy.
    De La Cruz P, Guerrero A, Paniego J, Arranz I, Moreno A, Sánchez De La Cuesta F.
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb 01; 365(2):96-101. PubMed ID: 11819026
    [Abstract] [Full Text] [Related]

  • 10. Effect of aspirin plus dipyridamole on the retinal vascular pattern in experimental diabetes mellitus.
    De la Cruz JP, Moreno A, Muñoz M, García Campos JM, Sánchez de la Cuesta F.
    J Pharmacol Exp Ther; 1997 Jan 01; 280(1):454-9. PubMed ID: 8996228
    [Abstract] [Full Text] [Related]

  • 11. Prostacyclin-thromboxane balance and retinal vascular pattern in rats with experimentally induced diabetes.
    Moreno A, De La Cruz JP, Garcia Campos J, Sanchez De La Cuesta F.
    Can J Ophthalmol; 1995 Apr 01; 30(3):117-23. PubMed ID: 7627895
    [Abstract] [Full Text] [Related]

  • 12. Gender differences in the effect of aspirin on retinal ischemia, prostanoid synthesis and nitric oxide production in experimental type 1-like diabetes.
    González-Correa JA, Arrebola MM, Muñoz-Marín J, Moreno A, Guerrero A, Arranz I, De La Cuesta FS, De La Cruz JP.
    Vascul Pharmacol; 2007 Apr 01; 47(2-3):83-9. PubMed ID: 17581795
    [Abstract] [Full Text] [Related]

  • 13. Virgin olive oil administration improves the effect of aspirin on retinal vascular pattern in experimental diabetes mellitus.
    De La Cruz JP, Del Río S, López-Villodres JA, Villalobos MA, Jebrouni N, González-Correa JA.
    Br J Nutr; 2010 Aug 01; 104(4):560-5. PubMed ID: 20350343
    [Abstract] [Full Text] [Related]

  • 14. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils.
    Koike H, Imanishi N, Natsume Y, Morooka S.
    Eur J Pharmacol; 1994 Nov 15; 269(3):299-309. PubMed ID: 7895770
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of PAF-induced platelet aggregation by WEB 2086 'in-vitro', an antagonist to the receptor for platelet-activating factor, in bovine.
    da Silva MB, Herion F, Raskinet R, David JL, Gustin P, Dessy C, Lekeux P.
    Zentralbl Veterinarmed A; 1996 Sep 15; 43(7):399-413. PubMed ID: 8921726
    [Abstract] [Full Text] [Related]

  • 16. Effect of camonagrel, a selective thromboxane synthase inhibitor, on retinal vascularization in experimental diabetes.
    De La Cruz JP, Moreno A, Ruiz-Ruiz MI, García Campos J, Sánchez de la Cuesta F.
    Eur J Pharmacol; 1998 May 29; 350(1):81-5. PubMed ID: 9683018
    [Abstract] [Full Text] [Related]

  • 17. Formation of a highly stable complex between BN 50730 [tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4] and the platelet-activating factor receptor in rabbit platelet membranes.
    Silva CL, Cruz HN, Violante FA, Cordeiro RS, Martins MA, Noël F.
    Biochem Pharmacol; 1996 Jan 26; 51(2):193-6. PubMed ID: 8615889
    [Abstract] [Full Text] [Related]

  • 18. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM, Fraisse L, Bachy A, Valette G, Savi P, Laplace MC, Lassalle J, Roche B, Lale A, Keane PE.
    J Lipid Mediat; 1993 Aug 26; 8(1):31-51. PubMed ID: 8257776
    [Abstract] [Full Text] [Related]

  • 19. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
    Crowley HJ, Yaremko B, Selig WM, Janero DR, Burghardt C, Welton AF, O'Donnell M.
    J Pharmacol Exp Ther; 1991 Oct 26; 259(1):78-85. PubMed ID: 1656030
    [Abstract] [Full Text] [Related]

  • 20. Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).
    Fujita M, Seki T, Inada H, Shimizu K, Takahama A, Sano T.
    Bioorg Med Chem Lett; 2002 Mar 11; 12(5):771-4. PubMed ID: 11858999
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.